Neurotransmitters

Before Otto Loewi's famous 1921 experiment, the question of how one neuron communicates with the next was unresolved. Loewi filled two beating frog hearts with saline solution and stimulated the vagus nerve of the first heart, slowing it down. He then transferred the saline to the second heart — and it slowed too. The saline had carried a chemical signal: what he called "Vagusstoff", later identified as acetylcholine. This discovery, shared with Henry Dale in the 1936 Nobel Prize in Physiology or Medicine, established that neurons communicate not only by electrical impulses but by releasing chemical messengers across the synaptic cleft. These messengers — neurotransmitters — are now understood to be the molecular substrate of virtually every psychological process, from perception and memory to mood, motivation, and psychopathology.

From rapid point-to-point transmission to slow diffuse modulation.

Neurotransmitter systems differ fundamentally in the speed and spatial scope of their signalling. Amino acid transmitters act in milliseconds at discrete synapses; neuropeptides diffuse widely and act over minutes. This difference reflects a fundamental division between fast synaptic communication and slow neuromodulation.

Amino acidsFast · Local · Milliseconds

Glutamate & GABA

The primary excitatory (glutamate) and inhibitory (GABA) transmitters in the brain. Act on ionotropic receptors — ligand-gated ion channels that open within milliseconds of binding, producing rapid, spatially confined changes in membrane potential. Glutamate drives depolarisation via AMPA and NMDA receptors; GABA drives hyperpolarisation via GABA-A receptors. Together they account for the majority of synaptic transmission.

Ionotropic · Sub-millisecond · Point-to-point
AcetylcholineFast & slow · Peripheral & central

Acetylcholine

Acts on both ionotropic (nicotinic) and metabotropic (muscarinic) receptors, giving it both fast and slow signalling capabilities. In the periphery it controls voluntary muscle contraction and autonomic visceral function; in the CNS it is released from the basal forebrain to modulate cortical arousal, attention, and memory encoding. Degeneration of basal forebrain cholinergic neurons is the most characteristic neurochemical finding in Alzheimer's disease.

Nicotinic (fast) & muscarinic (slow) · Memory & autonomic
MonoaminesSlow · Diffuse · Seconds to minutes

Dopamine, Serotonin & Norepinephrine

Act predominantly on metabotropic (G-protein-coupled) receptors, triggering intracellular signalling cascades that alter neuronal excitability over seconds to minutes. Released from discrete nuclei (ventral tegmental area, raphe nuclei, locus coeruleus) they modulate broad cortical and subcortical regions, biasing psychological states — motivation, mood, and arousal — rather than carrying specific sensory or motor information. The primary targets of most psychiatric drugs.

Metabotropic · Neuromodulatory · Wide broadcast
NeuropeptidesSlowest · Most diffuse · Minutes to hours

Neuropeptides

Large molecules (e.g., substance P, oxytocin, endorphins, CRH) released in small quantities, often co-released with classical transmitters. They bind metabotropic receptors and act via volume transmission — diffusing widely through extracellular fluid rather than operating at discrete synapses. Their effects unfold over minutes to hours and shape long-term states such as pain sensitivity, social bonding, and stress responses.

Volume transmission · Longest timescale · Behavioural states

Otto Loewi

1873–1961

German pharmacologist whose 1921 frog-heart experiment demonstrated for the first time that neuronal communication at the periphery occurs chemically rather than purely electrically — identifying 'Vagusstoff' (later shown to be acetylcholine) as the substance released by vagal stimulation. Shared the 1936 Nobel Prize in Physiology or Medicine with Henry Dale for this discovery, which established the conceptual foundation for neurotransmitter research.

Henry Dale

1875–1968

British pharmacologist who identified acetylcholine as a physiologically active substance and established Dale's principle — the generalisation that a neuron releases the same neurotransmitter at all its terminals. Dale and his collaborators distinguished between nicotinic and muscarinic effects of acetylcholine, laying the groundwork for receptor pharmacology and the classification of neurotransmitter actions.

Bernard Katz

1911–2003

British biophysicist who established the quantal hypothesis of neurotransmitter release: neurotransmitters are released in discrete packets (quanta), each corresponding to the contents of a single synaptic vesicle. His work at the neuromuscular junction established the mechanism of calcium-triggered vesicular fusion that underlies all fast synaptic transmission. Shared the 1970 Nobel Prize with Axelrod and Ulf von Euler.

Julius Axelrod

1912–2004

American pharmacologist who discovered that reuptake — not enzymatic degradation — is the primary mechanism for clearing norepinephrine from the synapse, identifying transporter proteins as the key molecular target. This discovery transformed psychopharmacology by revealing how tricyclic antidepressants and stimulants work, and opened the path to the development of SSRIs and SNRIs. Shared the 1970 Nobel Prize in Physiology or Medicine.

Chemical synapse

The specialised junction between two neurons (or a neuron and its target cell) at which communication occurs through the release and reception of chemical neurotransmitters. The presynaptic terminal contains vesicles packed with neurotransmitter; when an action potential arrives and opens voltage-gated calcium channels, the vesicles fuse with the membrane and release their contents into the synaptic cleft — a gap of approximately 20 nanometres. The transmitter diffuses across and binds to receptors on the postsynaptic membrane, altering its excitability.

Excitatory and inhibitory transmission

Neurotransmitters do not carry information as such — they alter the probability that the postsynaptic neuron will fire. Excitatory transmitters (primarily glutamate) depolarise the postsynaptic membrane, bringing it closer to the action potential threshold. Inhibitory transmitters (primarily GABA) hyperpolarise it, pushing it further from threshold. A postsynaptic neuron integrates thousands of excitatory and inhibitory inputs simultaneously; whether it fires depends on the net sum of these inputs — a process of spatial and temporal summation.

Reuptake

The primary mechanism by which neurotransmitter action is terminated for monoamine systems: transporter proteins embedded in the presynaptic membrane actively pump the neurotransmitter back into the terminal, where it can be repackaged for re-release. Julius Axelrod's demonstration that norepinephrine is cleared primarily by reuptake rather than enzymatic degradation revealed transporters as drug targets. Drugs that block reuptake — including SSRIs (serotonin), SNRIs (serotonin and norepinephrine), and amphetamines (dopamine and norepinephrine) — increase the concentration of transmitter in the synaptic cleft, prolonging and amplifying postsynaptic effects.

Ionotropic receptors

Receptors that are themselves ion channels: binding of a neurotransmitter directly opens the channel, allowing ions to flow across the membrane within milliseconds. Examples include AMPA receptors (sodium/potassium, excitatory), NMDA receptors (calcium, excitatory — also require depolarisation and glycine as a co-agonist), and GABA-A receptors (chloride, inhibitory). Benzodiazepines enhance GABA-A function by increasing the frequency of chloride channel opening without binding to the GABA site itself.

Metabotropic receptors

G-protein-coupled receptors (GPCRs) that do not directly control ion channels; instead, binding of a neurotransmitter activates an intracellular G-protein, which triggers a cascade of second-messenger signalling (cAMP, inositol phosphate pathways) that modulates ion channels and gene expression indirectly. The response is slower (seconds to minutes) and more prolonged than ionotropic signalling. All dopamine receptors, most serotonin receptors, and muscarinic acetylcholine receptors are metabotropic. The majority of psychotropic drugs act on this class of receptor.

Neuromodulation

A mode of neurotransmitter action in which a chemical messenger alters the gain or responsiveness of neurons without directly driving them to fire or preventing them from doing so. Neuromodulators — dopamine, serotonin, norepinephrine, acetylcholine — are released from diffuse projection systems and bias the activity of large neuronal populations, effectively tuning the signal-to-noise ratio of information processing. Disruption of neuromodulatory systems underlies most major psychiatric disorders: deficient dopamine modulation in the prefrontal cortex is implicated in the cognitive symptoms of schizophrenia; reduced serotonin tone in the monoamine hypothesis of depression; locus coeruleus norepinephrine hyperactivity in PTSD.

What is a neurotransmitter?+

A neurotransmitter is a chemical messenger released by a neuron into the synaptic cleft — the gap between two neurons — that alters the activity of the receiving (postsynaptic) neuron by binding to specialised receptor proteins. To qualify as a neurotransmitter by classical criteria, a substance must be synthesised in the neuron, released in response to neuronal activity, produce a defined effect on the postsynaptic cell, and be removed from the synapse by a specific mechanism. The major neurotransmitters include glutamate (the brain's primary excitatory transmitter), GABA (the primary inhibitory transmitter), acetylcholine, and the monoamines — dopamine, serotonin, and norepinephrine.

What is the difference between ionotropic and metabotropic receptors?+

Ionotropic receptors are ion channels that open directly when a neurotransmitter binds to them, allowing specific ions to flow across the membrane within milliseconds — producing fast, localised changes in excitability. Examples include AMPA, NMDA, and GABA-A receptors. Metabotropic receptors are G-protein-coupled receptors that do not control ion channels directly; instead they trigger intracellular signalling cascades that produce slower, longer-lasting changes in neuronal activity over seconds to minutes. Dopamine, serotonin, and muscarinic acetylcholine receptors are metabotropic. The clinical implication is that drugs targeting metabotropic receptors tend to have more prolonged effects and more diffuse targets than those acting on ionotropic channels.

How do psychiatric drugs work on neurotransmitter systems?+

Most psychiatric drugs act by manipulating one of three points in the neurotransmitter cycle: synthesis, release, or termination. Reuptake inhibitors (SSRIs, SNRIs, amphetamines) block transporter proteins to increase the concentration of transmitter in the synapse. Receptor agonists mimic a transmitter and activate its receptors; antagonists block receptors and reduce signalling. Enzyme inhibitors (e.g., MAO inhibitors) slow the degradation of monoamines, increasing their availability. Some drugs act on autoreceptors — presynaptic receptors through which the neuron monitors its own transmitter release and adjusts output accordingly. The specificity and therapeutic window of a drug depends on which receptor subtypes it targets and in which brain regions they are expressed.

What is the difference between a neurotransmitter and a neuromodulator?+

The terms describe different modes of action rather than different molecules — the same substance can act as both depending on context. Classical neurotransmitters act rapidly at discrete, well-defined synapses, directly changing the firing probability of a specific postsynaptic neuron. Neuromodulators — typically the monoamines and acetylcholine — act more diffusely, released from widespread projection systems to modulate the gain or sensitivity of large neuronal populations without directly driving or suppressing firing. In practice, dopamine, serotonin, and norepinephrine are often described as neuromodulators because their primary function is to bias information processing broadly (setting the 'tone' for reward, mood, and arousal) rather than to carry specific sensory or motor signals.

Last reviewed August 2025
  1. 1.

    Loewi O. (1921). Über humorale Übertragbarkeit der Herznervenwirkung. Pflügers Archiv für die gesamte Physiologie, 189(1), 239–242.

    +About this source

    The original demonstration of chemical neurotransmission using the frog heart preparation.

  2. 2.

    Dale H.H. & Feldberg W. (1934). Chemical transmission at motor nerve endings in voluntary muscle. Journal of Physiology, 81(1), 39–80.

    +About this source

    Identified acetylcholine as the transmitter at the neuromuscular junction and established the chemical transmission framework in the peripheral nervous system.

  3. 3.

    Axelrod J. (1961). Enzymatic formation of adrenaline and other catechols from monophenols. Science, 134(3476), 343.

    +About this source

    Key paper establishing catecholamine synthesis pathways; part of the Nobel-prize-winning programme identifying reuptake as the termination mechanism.

  4. 4.

    Katz B. (1966). Nerve, Muscle, and Synapse. McGraw-Hill.

    +About this source

    Classic account of quantal neurotransmitter release and the vesicular hypothesis of synaptic transmission.

  5. 5.

    Stahl S.M. (2021). Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (5th ed.). Cambridge University Press.

    +About this source

    Leading clinical psychopharmacology textbook covering neurotransmitter systems, receptor pharmacology, and mechanisms of psychiatric drug action.

  6. 6.

    Cooper J.R., Bloom F.E. & Roth R.H. (2003). The Biochemical Basis of Neuropharmacology (8th ed.). Oxford University Press.

    +About this source

    Comprehensive reference on the neurochemistry of neurotransmitter systems and their pharmacological modulation.